Combi-2

General Information


DRACP ID  DRACP02035

Peptide Name   Combi-2

Sequence  FRWWHR

Sequence Length  6

UniProt ID  Not available

PubChem CID  Not available

Origin  porcine cathelicidin peptide

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Jurkat Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia Leukemia IC50 ≥ 65 µM MTT assay 24h 1

Hemolytic Activity  RBC: IC50 ≥ 65 µM

Normal (non-cancerous) Cytotoxicity  PBMC: IC50 ≥ 65 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02035

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C49H62N16O7

Absent amino acids  ACDEGIKLMNPQSTVY

Common amino acids  RW

Mass  107649

Pl  12.5

Basic residues  3

Acidic residues  0

Hydrophobic residues  3

Net charge  3

Boman Index  -2686

Hydrophobicity  -186.67

Aliphatic Index  0

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  11000

Absorbance 280nm  2200

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 32126228

Title  Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin

Doi 10.1016/j.bbamem.2020.183228

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.